Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.67 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.57 |
| ▸ | PTGDR | Q13258 | 8/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | PKLR | P30613 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841106 | 0.92 | DHCR7 (0.60) | DHCR7PTGDR2PTGDR | |
| SCHEMBL12209246 | 0.83 | HTT (0.66) | DHCR7PKMNPC1PKLRRAB9A | |
| SCHEMBL16788114 | 0.82 | HTT (0.69) | DHCR7PKMSMN1; SMN2NPC1PKLR | |
| SCHEMBL16080246 | 0.82 | DHCR7 (0.73) | DHCR7PTGDR2PTGDRSMN1; SMN2MCOLN3 | |
| SCHEMBL10175759 | 0.82 | DHCR7 (0.73) | DHCR7PTGDR2PTGDRSMN1; SMN2MCOLN3 | |
| SCHEMBL19457374 | 0.81 | MCOLN3 (0.75) | HSD11B1PKMMCOLN3 | |
| SCHEMBL27652326 | 0.80 | DHCR7 (0.60) | DHCR7PTGDR2PTGDRPKMMAPT | |
| SCHEMBL29483645 | 0.79 | LMNA (0.69) | DHCR7SMN1; SMN2 | |
| SCHEMBL19348522 | 0.79 | DHCR7 (0.59) | DHCR7PTGDR2PTGDRPKMNPC1 | |
| SCHEMBL1096258 | 0.79 | DHCR7 (0.59) | DHCR7PTGDR2PTGDRPKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| US-8153793-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153793-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| EP-2407453-A1 | PGD2 receptor antagonist | Shionogi & Co., Ltd. (JP) | 2012-01-18 | — | — | EP | disclosed |
| EP-2407459-A1 | Synthetic intermediate in the production of a sulfonamide derivative having PGD2 receptor antagonistic activity | Shionogi & Co., Ltd. (JP) | 2012-01-18 | — | — | EP | disclosed |
| EP-1939175-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi&Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, PTGDR2, CNR2 | DHCR7 2162/4885PTGDR2 2/4885PTGDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.